Focused On-demand Library for Gamma-adducin

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9UEY8

UPID:

ADDG_HUMAN

Alternative names:

Adducin-like protein 70

Alternative UPACC:

Q9UEY8; D3DRA8; O43243; Q5VU09; Q92773; Q9UEY7

Background:

Gamma-adducin, also known as Adducin-like protein 70, is a membrane-cytoskeleton-associated protein pivotal in promoting the assembly of the spectrin-actin network. It plays a crucial role in actin filament capping and binds to calmodulin. This protein is involved in the regulation of vascular smooth muscle cells, affecting renal and cerebral blood flow, and plays a significant role in podocyte structure and function.

Therapeutic significance:

Gamma-adducin's involvement in cerebral palsy, spastic quadriplegic 3, a neurodevelopmental disorder characterized by spasticity and cognitive impairment, underscores its therapeutic potential. Understanding the role of Gamma-adducin could open doors to potential therapeutic strategies for this condition.